Thiotepa-Fludarabine-Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from unrelated donors in patients with AML relapsing from prior allogeneic HSCT - TFT 2 Tx

Trial Profile

Thiotepa-Fludarabine-Treosulfan (TFT) conditioning for 2nd allogeneic PBSCT from unrelated donors in patients with AML relapsing from prior allogeneic HSCT - TFT 2 Tx

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Apr 2017

At a glance

  • Drugs Fludarabine (Primary) ; Thiotepa (Primary) ; Treosulfan (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms TFT 2 Tx
  • Most Recent Events

    • 11 Aug 2014 New source identified and integrated (European Clinical Trials Database record: EudraCT2012-005414-18)
    • 04 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top